Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
Andrea J. Pruijssers(Vanderbilt Health), Timothy P. Sheahan(University of North Carolina at Chapel Hill), David R. Martinez(University of North Carolina at Chapel Hill), Ralph S. Baric(University of North Carolina at Chapel Hill), Kendra L. Gully(University of North Carolina at Chapel Hill), Joy Y. Feng(Gilead Sciences (United States)), Rachel L. Graham(University of North Carolina at Chapel Hill), Darius Babusis(Gilead Sciences (United States)), Bin Ma(Tongji University), Tomáš Cihlář(Gilead Sciences (United States)), Venice Du Pont(Gilead Sciences (United States)), Tia M. Hughes(Vanderbilt University Medical Center), Sarah R. Leist(University of North Carolina at Chapel Hill), Boyd L. Yount(University of North Carolina at Chapel Hill), Laura J. Stevens(Vanderbilt University Medical Center), Xiaotao Lu(Vanderbilt University Medical Center), Danielle Porter(Gilead Sciences (United States)), Kenneth H. Dinnon(University of North Carolina at Chapel Hill), John P. Bilello(Global Vaccines (United States)), Mark R. Denison(Bipar), Amelia S. George(Vanderbilt University Medical Center), James D. Chappell(King Saud bin Abdulaziz University for Health Sciences), Jared Pitts(Gilead Sciences (United States)), Eisuke Murakami(Gilead Sciences (United States)), Maria L. Agostini(VIR Biotechnology (United States)), Ariane J. Brown(University of North Carolina at Chapel Hill), Alexandra Schäfer(University of North Carolina at Chapel Hill), Lisa E. Gralinksi(University of North Carolina at Chapel Hill), Jason K. Perry(Pulmatrix (United States))
Cited by 541
Related Papers
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
|New England Journal of Medicine|2015|3.4k
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children
|New England Journal of Medicine|2015|1.9k
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k